Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Stocks in this Quantisnow insightHealth Care
Historical context for NUVB
Across the 24 sessions after earlier NUVB headlines, the stock closed higher 14 times and lower 10 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NUVB | SPY |
|---|---|---|---|
| May 7, 2026 | Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer | -4.6% | -0.3% |
| May 6, 2026 | Nuvation Bio to Participate in Upcoming Investor Conferences | +4.3% | +1.4% |
| May 5, 2026 | Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update | +9.5% | +0.8% |
| Apr 27, 2026 | Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers | -6.7% | +0.2% |
| Apr 22, 2026 | /U P D A T E -- Nuvation Bio Inc./and 1 other headline that session | +0.2% | +1.0% |
| Apr 21, 2026 | Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 | -0.2% | -0.7% |
Quantisnow market dataNYSE
NUVB
Nuvation Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for NUVB
Full NUVB profile on Quantisnow Follow NUVB and get a push notification the moment its next story breaks.